Last updated: May 22, 2023
Sponsor: Northwestern University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Contraception
Treatment
Ulipristal Acetate
Clinical Study ID
NCT05285605
STU00215994
Ages 16-40 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 16-40 years of age
- English-speaking
- In a sexual relationship with possibility of pregnancy
- Delivered a live infant
- Desire to delay pregnancy for at least a year
- A patient at Northwestern University Feinberg School of Medicine Department ofObstetrics and Gynecology
- Choosing no postpartum contraceptive method or a lower efficacy method: condoms,female condoms, diaphragm/cervical cap/sponge, fertility awareness method
Exclusion
Exclusion Criteria:
- Allergy to UPA
- Those who have had tubal sterilization
- Those who conceived via assisted reproductive technology
- Those with inability to follow up
- Those taking drugs that interact with UPA (CYP3A4 inducers, abametapir, felbamate,fexinidazole, fusidic acid, griseofulvin, oxcarbazepine, progestins, topiramate)
Study Design
Total Participants: 75
Treatment Group(s): 1
Primary Treatment: Ulipristal Acetate
Phase:
Study Start date:
March 01, 2022
Estimated Completion Date:
June 30, 2023
Study Description
Connect with a study center
Northwestern Medicine Prentice Women's Hospital
Chicago, Illinois 60611
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.